Counterfeit Obesity Drugs Under Scrutiny
A recent report published in The Lancet has raised serious concerns about the growing circulation of fake and falsified obesity drugs. Driven by high treatment costs, lack of insurance coverage, and increasing demand for rapid weight loss, counterfeit medications are emerging as a major public health risk.
Global Spread of Fake GLP-1 Drugs
Health journalist Sophie Cousins highlights the widespread availability of counterfeit versions of Ozempic and Mounjaro, particularly in tourist areas in Mexico and pharmacies along the US border.
These drugs belong to the GLP-1 receptor agonist class, which helps manage diabetes and obesity by suppressing appetite and improving satiety. As a result, they have gained immense popularity for both medical and weight-loss purposes.
Unprecedented Scale of Drug Fraud
According to Shabbir Safdar, executive director of the Partnership for Safe Medicines, the level of fraud involving weight-loss injectables is unprecedented. He emphasises that counterfeit versions of these drugs now appear highly convincing, with nearly identical packaging and labelling.
Moreover, many of these fake products are believed to originate in Mexico and are often resold at significantly lower prices, attracting unsuspecting buyers.
Hidden Dangers of Counterfeit Medications
Although these drugs may look authentic, counterfeit GLP-1 receptor agonists pose serious health risks. Studies indicate that such products may contain incorrect dosages, harmful substances, or no active ingredients at all.
Consequently, patients may experience ineffective treatment or severe complications, including hyperglycaemia and cardiovascular issues.
Regulatory Warnings and Seizures
In response to the growing threat, the US Food and Drug Administration issued a warning in December 2025 after seizing multiple counterfeit Ozempic products circulating outside authorised supply chains. The agency also reported several adverse events linked to these falsified drugs.
WHO Flags Global Surge in Fake Drugs
Similarly, the World Health Organization has reported a sharp increase in falsified GLP-1 drugs across nearly 60 countries.
As reported by The Hindu, the organisation attributes this surge to rising demand, self-diagnosis, self-prescription practices, and the rapid growth of unregulated online pharmaceutical sales. Furthermore, the potential introduction of tablet forms may make these drugs even easier to counterfeit at scale.
Call for Safe and Supervised Use
In light of these risks, WHO strongly recommends that patients use GLP-1 receptor agonists only under the supervision of qualified healthcare professionals. Proper prescribing, dosing, and follow-up are essential to ensure both safety and effectiveness.
Access, Affordability, and Social Implications
Beyond safety concerns, Alexandra Brewis from Arizona State University highlights the broader social challenges surrounding obesity treatment. She notes that high costs and limited access make it difficult for many individuals to obtain these medications.
As a result, societal perceptions may increasingly stigmatise individuals with obesity, overlooking the financial and structural barriers they face.
Conclusion: A Growing Public Health Challenge
Overall, the rise of counterfeit weight-loss drugs reflects a complex intersection of demand, affordability, and access. Therefore, strengthening regulation, improving awareness, and ensuring equitable access to safe treatments remain critical to addressing this emerging global health threat.